Lexicon Pharmaceuticals' Heart-Failure Treatment Inpefa Gets FDA Approval
May 26 2023 - 4:49PM
Dow Jones News
By Sabela Ojea
Lexicon Pharmaceuticals said Friday that the Food and Drug
Administration has approved its Inpefa treatment, aimed at reducing
heart failures.
The biopharmaceutical company said Inpefa is expected to be
commercially available in the U.S. market by the end of June.
Inpefa, a once-daily oral tablet known generically as
sotagliflozin, targets the risk of cardiovascular death, urgent
heart failure medical visits and hospitalizations in adults with
heart failure of type 2 diabetes mellitus and chronic kidney
disease, among other cardiovascular risk factors.
Shares rose 0.9% to $3.21 in after-hours trading.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 26, 2023 16:34 ET (20:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From May 2024 to Jun 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2023 to Jun 2024
